Sign up Australia
Proactive Investors - Run By Investors For Investors

Benitec Biopharma acquires U.S. based Tacere Therapeutics

Benitec Biopharma acquires U.S. based Tacere Therapeutics

Benitec Biopharma (ASX: BLT) has completed the acquisition of U.S.-based RNA interference (RNAi) therapeutics company Tacere Therapeutics, providing Benitec with an advanced preclinical asset.

With the acquisition complete, Benitec has the opportunity to enter the clinic in mid-2013 with Tacere’s Phase I/IIa ready therapeutic program in hepatitis C that use Benitec’s novel gene silencing technology, ddRNAi.

The pre-clinical data and safety profile of TT-034 positions Benitec to begin clinical trials in hepatitis C at a time when a number of high profile HCV therapies are encountering safety concerns.

Importantly, successful Phase II clinical data is a key driver to securing deals with major pharmaceutical companies.

The worldwide market for new hepatitis C treatments is projected to reach $20 billion by 2020.

Hepatitis C virus (HCV) infection is a leading cause of liver disease worldwide, with no known cure apart from liver transplantation.

The World Health Organisation estimates around 170 million people are chronically infected, with 350,000 deaths from HCV-related liver disease each year.

Tacere has also been conducting extensive preclinical work in the area of macular degeneration, with promising early results.

The company has been successfully developing programs utilising Benitec's proprietary ddRNAi technology since 2006.


Proactive Investors is a market leader in the investment news space, providing ASX “Small and Mid-cap” company news, research reports, StockTube videos and One2One Investor Forums.



Register here to be notified of future BLT Company articles
View full BLT profile

Benitec Biopharma Timeline

Newswire
August 18 2015
Newswire
November 11 2014

Related Articles

Bankroll.jpg
March 02 2017
The new funds will be used to expand the pre-clinical and early-clinical development of the company’s immuno-oncology drug, Clevegen
Novogen: Access latest PPT from Proactive's CEO Sessions
April 13 2017
Dr James Garner talked clinical-stage programs with investors.
GW_Pharma.png
January 11 2017
“[We are] entering a very exciting phase, which should result in the crystallisation of substantial value,” said chief executive, Dr Satu Vainikka.

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use